This study identified six lncRNAs (SLC12A5-AS1, MAP3K2-DT, LINC02544, MIR181A2HG, LINC01914, and LNCOG) whose expression is significantly upregulated in gastric cancer. High expression of these lncRNAs is associated with unfavourable overall survival, particularly for LNCOG, LINC02544, and SLC12A5-AS1 after adjustment. Co-expression network analyses highlighted the involvement of these lncRNAs in cancer-associated pathways, notably epithelial-mesenchymal transition. These lncRNAs may hold diagnostic and prognostic value, although independent validations are required.
This retrospective study assessed the prognostic value of tumor mutational burden (TMB) in 221 patients with metastatic colorectal cancer (mCRC) receiving anti-PD-1/PD-L1 immunotherapy combined with standard chemotherapy. Patients with high TMB (TMB-H) demonstrated significantly improved progression-free survival and overall survival compared to those with low TMB (TMB-L). Furthermore, the TMB-H group reported a better post-treatment quality of life, with no increase in adverse events. These findings suggest that TMB-H is a positive prognostic biomarker in this patient population and warrant prospective validation.
This study longitudinally analyzed circulating tumor DNA (ctDNA) in 42 patients with advanced melanoma treated with immune checkpoint inhibitors. ctDNA levels significantly correlated with radiological response according to RECIST 1.1 and total tumor volume, especially when measurements were temporally aligned. Although the discriminative performance for identifying progression was moderate, higher ctDNA thresholds demonstrated better specificity. The study also revealed marked heterogeneity in ctDNA shedding across metastatic sites, highlighting its potential as a complementary biomarker for disease monitoring.
This study evaluates the performance of the DNA methylation-based Bethesda Classifier v3 (Bv3) for central nervous system (CNS) tumor diagnosis. Bv3 was tested on 516 samples, including straightforward cases and diagnostically challenging cases previously unclassifiable by the Heidelberg Classifier v12.8. It achieved correct classification in 97% of straightforward cases and successfully classified 56% of complex cases, with a low misclassification rate of 4%. The findings suggest that Bv3 is a robust complementary tool for routine neuropathological diagnostics, even for samples with low DNA concentration.